

# Psychedelic Microdosing Market Forecasts to 2032 – Global Analysis By Component (Psilocybin, Ketamine, MDMA and Other Compounds), Route of Administration, Distribution Channel, Application and By Geography

<https://marketpublishers.com/r/PE0B14D91CECEN.html>

Date: September 2025

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: PE0B14D91CECEN

## Abstracts

According to Statistics MRC, the Global Psychedelic Microdosing Market is accounted for \$2.1 billion in 2025 and is expected to reach \$5.8 billion by 2032 growing at a CAGR of 15% during the forecast period. Psychedelic microdosing refers to the practice of consuming very small, sub-perceptual doses of psychedelic substances such as LSD or psilocybin, typically around one-tenth to one-twentieth of a recreational dose. Unlike full psychedelic experiences that cause hallucinations and intense alterations in perception, microdosing aims to deliver subtle cognitive, emotional, and physiological benefits without significantly impairing daily functioning. Advocates suggest that microdosing may enhance creativity, focus, mood stability, and emotional well-being, while reducing anxiety or depression symptoms. Although gaining popularity for potential mental health and productivity benefits, scientific research on its safety, efficacy, and long-term effects remains limited and ongoing.

Market Dynamics:

Driver:

Rising demand for new mental-health treatments

The rising prevalence of depression, anxiety, and PTSD has exposed the shortcomings of conventional treatments. Microdosing psychedelics is gaining attention for its ability to elevate mood, sharpen focus, and promote mental well-being with reduced adverse

effects. Increasing public awareness combined with positive clinical findings is fostering greater acceptance among both patients and medical professionals. This momentum is driving investments in the development of safe, regulated psychedelic therapies. Consequently, the market is experiencing rapid expansion and wider utilization.

#### Restraint:

##### Limited high-quality clinical evidence for microdosing

Lack of robust clinical trials makes regulatory authorities cautious about granting approval or support for microdosing. Insufficient validation also diminishes investor trust and limits financial backing for research and commercialization. Limited scientific proof further discourages healthcare professionals from recommending its use. Consumer adoption therefore remains slow and is primarily shaped by anecdotal experiences rather than clinical validation. In turn, the shortage of reliable evidence hinders market expansion and delays wider acceptance.

#### Opportunity:

##### New product formats & distribution channels

Innovative product forms such as capsules, gummies, nasal sprays, and sublingual strips offer convenient and precise dosing. These formats appeal to a wider consumer base by making microdosing more approachable and less stigmatized. Online platforms, telehealth services, and wellness clinics further enhance distribution by providing discreet and safe access. Retail partnerships and digital marketplaces also help increase visibility and consumer trust. Together, these advancements drive broader adoption and market growth.

#### Threat:

##### Regulatory & legal barriers

Strict drug classification laws in many countries restrict research, clinical trials, and therapeutic applications of psychedelics. Lengthy approval processes and complex compliance requirements slow down innovation and market entry for new players. The lack of harmonized global regulations further limits cross-border collaboration and expansion. Fear of legal repercussions discourages investment and business

development in the sector. Overall, these barriers delay adoption and restrict the market's growth potential.

### Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the psychedelic microdosing market. On one hand, restrictions on clinical trials and research slowed product development and regulatory progress. Supply chain disruptions also affected access to raw materials and delivery of psychedelic-based products. However, the pandemic increased mental health challenges such as anxiety, depression, and stress, leading to growing interest in alternative therapies like microdosing. The shift toward telemedicine and digital mental health platforms further supported awareness and discussions around psychedelic microdosing during this period.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is expected to account for the largest market share during the forecast period, due to its growing acceptance in mental health research and therapy. Increasing clinical studies highlight psilocybin's effectiveness in treating depression, anxiety, and PTSD, driving demand for controlled microdosing. Rising public awareness and reduced stigma around natural psychedelics further encourage adoption. Additionally, regulatory bodies in some regions are easing restrictions, opening opportunities for commercial applications. Overall, psilocybin's strong therapeutic potential and shifting perceptions make it a key growth driver for the market.

The cognitive enhancement segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cognitive enhancement segment is predicted to witness the highest growth rate by attracting individuals seeking improved focus, creativity, and productivity. Rising interest from professionals, students, and entrepreneurs fuels demand as microdosing is increasingly viewed as a tool for mental performance optimization. Scientific studies and anecdotal evidence highlighting benefits like better problem-solving and memory retention further strengthen market adoption. The growing integration of nootropics and wellness trends also aligns with the microdosing movement, making it more mainstream. Overall, cognitive enhancement acts as a key driver by positioning microdosing as a performance-boosting lifestyle choice.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising mental health awareness and shifting societal attitudes toward alternative therapies. Increasing investment in research, clinical trials, and startup ecosystems is accelerating product innovation and development. Public discourse around wellness and personal productivity further strengthens demand. Supportive initiatives in certain U.S. states and Canadian regions foster progressive regulatory shifts, creating a more open environment. However, legal uncertainties and stigma remain challenges, though consumer interest and institutional backing continue to push market growth.

#### Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, owing to strong interest from wellness communities, mental health practitioners, and research organizations. Growing awareness of alternative treatments for anxiety, depression, and cognitive performance is shaping demand. Regulations are mixed across countries, creating both opportunities and barriers. Academic studies and clinical trials drive credibility, while wellness tourism and lifestyle trends also fuel curiosity. The cultural acceptance of holistic health practices supports adoption, though stricter legal frameworks in several nations slow down wider commercialization.

#### Key players in the market

Some of the key players profiled in the Psychedelic Microdosing Market include COMPASS Pathways, MindMed Inc., Cybin Inc., Atai Life Sciences, Beckley Psytech, Seelos Therapeutics, Delix Therapeutics, Eleusis, GH Research PLC, Awakn Life Sciences, Numinus Wellness, Mydecine Innovations Group, Enttheon Biomedical, Wesana Health, Tryp Therapeutics, Enveric Biosciences, and Clairvoyant Therapeutics.

#### Key Developments:

In April 2025, Cybin secured Strategic Partnership Agreements with 18 clinical sites for its Phase 3 CYB003 program. These collaborations aim to streamline operations, boost patient recruitment, and standardize protocols across the PARADIGM trial's multinational infrastructure.

In February 2024, MindMed partnered with Sphere Health to advance digital biomarkers and remote monitoring for psychedelic therapies, including microdosing. The

collaboration integrates wearable tech with clinical protocols to enhance patient tracking, dose-response analysis, and personalized treatment optimization.

In January 2024, COMPASS entered a three-year research collaboration with Greenbrook TMS to pilot COMP360 psilocybin therapy across U.S. clinics. The initiative targets treatment-resistant depression, optimizing therapist workflows, patient experience, and digital integration for scalable delivery.

#### Compounds Covered:

Psilocybin

LSD

Ketamine

MDMA

Other Compounds

#### Route of Administrations Covered:

Oral

Sublingual

Nasal

Transdermal

Other Route of Administrations

#### Distribution Channels Covered:

Prescription

Direct-to-consumer

Research supply

Applications Covered:

Mental health

Cognitive enhancement

Wellness and lifestyle

Addiction treatment

Home use

Other Applications

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

## Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL PSYCHEDELIC MICRODOSING MARKET, BY COMPOUND**

- 5.1 Introduction
- 5.2 Psilocybin
- 5.3 LSD
- 5.4 Ketamine
- 5.5 MDMA
- 5.6 Other Compounds

## **6 GLOBAL PSYCHEDELIC MICRODOSING MARKET, BY ROUTE OF ADMINISTRATION**

- 6.1 Introduction
- 6.2 Oral
- 6.3 Sublingual
- 6.4 Nasal
- 6.5 Transdermal
- 6.6 Other Route of Administrations

## **7 GLOBAL PSYCHEDELIC MICRODOSING MARKET, BY DISTRIBUTION CHANNEL**

- 7.1 Introduction
- 7.2 Prescription
- 7.3 Direct-to-consumer
- 7.4 Research supply

## **8 GLOBAL PSYCHEDELIC MICRODOSING MARKET, BY APPLICATION**

- 8.1 Introduction
- 8.2 Mental health
- 8.3 Cognitive enhancement
- 8.4 Wellness and lifestyle
- 8.5 Addiction treatment
- 8.6 Home use
- 8.7 Other Applications

## **9 GLOBAL PSYCHEDELIC MICRODOSING MARKET, BY GEOGRAPHY**

- 9.1 Introduction

## 9.2 North America

9.2.1 US

9.2.2 Canada

9.2.3 Mexico

## 9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 Italy

9.3.4 France

9.3.5 Spain

9.3.6 Rest of Europe

## 9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 New Zealand

9.4.6 South Korea

9.4.7 Rest of Asia Pacific

## 9.5 South America

9.5.1 Argentina

9.5.2 Brazil

9.5.3 Chile

9.5.4 Rest of South America

## 9.6 Middle East & Africa

9.6.1 Saudi Arabia

9.6.2 UAE

9.6.3 Qatar

9.6.4 South Africa

9.6.5 Rest of Middle East & Africa

## 10 KEY DEVELOPMENTS

10.1 Agreements, Partnerships, Collaborations and Joint Ventures

10.2 Acquisitions & Mergers

10.3 New Product Launch

10.4 Expansions

10.5 Other Key Strategies

## 11 COMPANY PROFILING

- 11.1 COMPASS Pathways
- 11.2 MindMed Inc.
- 11.3 Cybin Inc.
- 11.4 Atai Life Sciences
- 11.5 Beckley Psytech
- 11.6 Seelos Therapeutics
- 11.7 Delix Therapeutics
- 11.8 Eleusis
- 11.9 GH Research PLC
- 11.10 Awakn Life Sciences
- 11.11 Numinus Wellness
- 11.12 Mydecine Innovations Group
- 11.13 Enttheon Biomedical
- 11.14 Wesana Health
- 11.15 Tryp Therapeutics
- 11.16 Enveric Biosciences
- 11.17 Clairvoyant Therapeutics

## List Of Tables

### LIST OF TABLES

Table 1 Global Psychedelic Microdosing Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Psychedelic Microdosing Market Outlook, By Compound (2024-2032) (\$MN)

Table 3 Global Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) (\$MN)

Table 4 Global Psychedelic Microdosing Market Outlook, By LSD (2024-2032) (\$MN)

Table 5 Global Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) (\$MN)

Table 6 Global Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) (\$MN)

Table 7 Global Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) (\$MN)

Table 8 Global Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 9 Global Psychedelic Microdosing Market Outlook, By Oral (2024-2032) (\$MN)

Table 10 Global Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) (\$MN)

Table 11 Global Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) (\$MN)

Table 12 Global Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) (\$MN)

Table 13 Global Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) (\$MN)

Table 14 Global Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 15 Global Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) (\$MN)

Table 16 Global Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) (\$MN)

Table 17 Global Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) (\$MN)

Table 18 Global Psychedelic Microdosing Market Outlook, By Application (2024-2032) (\$MN)

Table 19 Global Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) (\$MN)

Table 20 Global Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) (\$MN)

Table 21 Global Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) (\$MN)

Table 22 Global Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) (\$MN)

Table 23 Global Psychedelic Microdosing Market Outlook, By Home use (2024-2032) (\$MN)

Table 24 Global Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 25 North America Psychedelic Microdosing Market Outlook, By Country (2024-2032) (\$MN)

Table 26 North America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) (\$MN)

Table 27 North America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) (\$MN)

Table 28 North America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) (\$MN)

Table 29 North America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) (\$MN)

Table 30 North America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) (\$MN)

Table 31 North America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) (\$MN)

Table 32 North America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 33 North America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) (\$MN)

Table 34 North America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) (\$MN)

Table 35 North America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) (\$MN)

Table 36 North America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) (\$MN)

Table 37 North America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) (\$MN)

Table 38 North America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 39 North America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) (\$MN)

Table 40 North America Psychedelic Microdosing Market Outlook, By Direct-to-

consumer (2024-2032) (\$MN)

Table 41 North America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) (\$MN)

Table 42 North America Psychedelic Microdosing Market Outlook, By Application (2024-2032) (\$MN)

Table 43 North America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) (\$MN)

Table 44 North America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) (\$MN)

Table 45 North America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) (\$MN)

Table 46 North America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) (\$MN)

Table 47 North America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) (\$MN)

Table 48 North America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 49 Europe Psychedelic Microdosing Market Outlook, By Country (2024-2032) (\$MN)

Table 50 Europe Psychedelic Microdosing Market Outlook, By Compound (2024-2032) (\$MN)

Table 51 Europe Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) (\$MN)

Table 52 Europe Psychedelic Microdosing Market Outlook, By LSD (2024-2032) (\$MN)

Table 53 Europe Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) (\$MN)

Table 54 Europe Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) (\$MN)

Table 55 Europe Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) (\$MN)

Table 56 Europe Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 57 Europe Psychedelic Microdosing Market Outlook, By Oral (2024-2032) (\$MN)

Table 58 Europe Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) (\$MN)

Table 59 Europe Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) (\$MN)

Table 60 Europe Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) (\$MN)

Table 61 Europe Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) (\$MN)

Table 62 Europe Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 63 Europe Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) (\$MN)

Table 64 Europe Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) (\$MN)

Table 65 Europe Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) (\$MN)

Table 66 Europe Psychedelic Microdosing Market Outlook, By Application (2024-2032) (\$MN)

Table 67 Europe Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) (\$MN)

Table 68 Europe Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) (\$MN)

Table 69 Europe Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) (\$MN)

Table 70 Europe Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) (\$MN)

Table 71 Europe Psychedelic Microdosing Market Outlook, By Home use (2024-2032) (\$MN)

Table 72 Europe Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 73 Asia Pacific Psychedelic Microdosing Market Outlook, By Country (2024-2032) (\$MN)

Table 74 Asia Pacific Psychedelic Microdosing Market Outlook, By Compound (2024-2032) (\$MN)

Table 75 Asia Pacific Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) (\$MN)

Table 76 Asia Pacific Psychedelic Microdosing Market Outlook, By LSD (2024-2032) (\$MN)

Table 77 Asia Pacific Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) (\$MN)

Table 78 Asia Pacific Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) (\$MN)

Table 79 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) (\$MN)

Table 80 Asia Pacific Psychedelic Microdosing Market Outlook, By Route of

Administration (2024-2032) (\$MN)

Table 81 Asia Pacific Psychedelic Microdosing Market Outlook, By Oral (2024-2032) (\$MN)

Table 82 Asia Pacific Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) (\$MN)

Table 83 Asia Pacific Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) (\$MN)

Table 84 Asia Pacific Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) (\$MN)

Table 85 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) (\$MN)

Table 86 Asia Pacific Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 87 Asia Pacific Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) (\$MN)

Table 88 Asia Pacific Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) (\$MN)

Table 89 Asia Pacific Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) (\$MN)

Table 90 Asia Pacific Psychedelic Microdosing Market Outlook, By Application (2024-2032) (\$MN)

Table 91 Asia Pacific Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) (\$MN)

Table 92 Asia Pacific Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) (\$MN)

Table 93 Asia Pacific Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) (\$MN)

Table 94 Asia Pacific Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) (\$MN)

Table 95 Asia Pacific Psychedelic Microdosing Market Outlook, By Home use (2024-2032) (\$MN)

Table 96 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 97 South America Psychedelic Microdosing Market Outlook, By Country (2024-2032) (\$MN)

Table 98 South America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) (\$MN)

Table 99 South America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) (\$MN)

- Table 100 South America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) (\$MN)
- Table 101 South America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) (\$MN)
- Table 102 South America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) (\$MN)
- Table 103 South America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) (\$MN)
- Table 104 South America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) (\$MN)
- Table 105 South America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) (\$MN)
- Table 106 South America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) (\$MN)
- Table 107 South America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) (\$MN)
- Table 108 South America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) (\$MN)
- Table 109 South America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) (\$MN)
- Table 110 South America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) (\$MN)
- Table 111 South America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) (\$MN)
- Table 112 South America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) (\$MN)
- Table 113 South America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) (\$MN)
- Table 114 South America Psychedelic Microdosing Market Outlook, By Application (2024-2032) (\$MN)
- Table 115 South America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) (\$MN)
- Table 116 South America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) (\$MN)
- Table 117 South America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) (\$MN)
- Table 118 South America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) (\$MN)
- Table 119 South America Psychedelic Microdosing Market Outlook, By Home use

(2024-2032) (\$MN)

Table 120 South America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 121 Middle East & Africa Psychedelic Microdosing Market Outlook, By Country (2024-2032) (\$MN)

Table 122 Middle East & Africa Psychedelic Microdosing Market Outlook, By Compound (2024-2032) (\$MN)

Table 123 Middle East & Africa Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) (\$MN)

Table 124 Middle East & Africa Psychedelic Microdosing Market Outlook, By LSD (2024-2032) (\$MN)

Table 125 Middle East & Africa Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) (\$MN)

Table 126 Middle East & Africa Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) (\$MN)

Table 127 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) (\$MN)

Table 128 Middle East & Africa Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 129 Middle East & Africa Psychedelic Microdosing Market Outlook, By Oral (2024-2032) (\$MN)

Table 130 Middle East & Africa Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) (\$MN)

Table 131 Middle East & Africa Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) (\$MN)

Table 132 Middle East & Africa Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) (\$MN)

Table 133 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) (\$MN)

Table 134 Middle East & Africa Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 135 Middle East & Africa Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) (\$MN)

Table 136 Middle East & Africa Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) (\$MN)

Table 137 Middle East & Africa Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) (\$MN)

Table 138 Middle East & Africa Psychedelic Microdosing Market Outlook, By Application (2024-2032) (\$MN)

Table 139 Middle East & Africa Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) (\$MN)

Table 140 Middle East & Africa Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) (\$MN)

Table 141 Middle East & Africa Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) (\$MN)

Table 142 Middle East & Africa Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) (\$MN)

Table 143 Middle East & Africa Psychedelic Microdosing Market Outlook, By Home use (2024-2032) (\$MN)

Table 144 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) (\$MN)

## I would like to order

Product name: Psychedelic Microdosing Market Forecasts to 2032 – Global Analysis By Component (Psilocybin, Ketamine, MDMA and Other Compounds), Route of Administration, Distribution Channel, Application and By Geography

Product link: <https://marketpublishers.com/r/PE0B14D91CECEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE0B14D91CECEN.html>